AMG 509 (xaluritamig), an anti-STEAP1 XmAb 2+ 1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer
O Nolan-Stevaux, C Li, L Liang, J Zhan, J Estrada… - Cancer Discovery, 2024 - AACR
The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in
most prostate tumors and at increased levels in metastatic castration-resistant prostate …
most prostate tumors and at increased levels in metastatic castration-resistant prostate …
[HTML][HTML] Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells
KR Parajuli, Y Jung, RS Taichman - Oncology Reports, 2024 - spandidos-publications.com
Prostate cancer (PCa) is one the most common malignancies in men. The high incidence of
bone metastasis years after primary therapy suggests that disseminated tumor cells must …
bone metastasis years after primary therapy suggests that disseminated tumor cells must …